Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|October 20, 2026

The BioPharm Brief: Lung Injury Survival, Alzheimer Prevention, and Longer Dosing Intervals

Nano24’s inhaled exosome therapy reduces mortality in a phase 2b ARDS trial, the FDA grants fast track designation to Nuravax’s preventive Alzheimer vaccine, and Bionyra’s long-acting anti-TL1A antibody shows a half-life that could support dosing every 3 to 6 months.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. We’re looking at survival data for a deadly lung condition, a regulatory boost for a vaccine designed to prevent Alzheimer disease, and an antibody that could mean fewer doses for people with inflammatory bowel disease.

First, Nano24’s inhaled EXO-CD24 has reduced mortality in a phase 2b trial in patients with acute respiratory distress syndrome, or ARDS. The therapy uses engineered exosomes, tiny cell-derived particles, to deliver an immune-regulating protein directly to the lungs. In the 90-patient study, 85% of patients receiving EXO-CD24 were free of respiratory failure at day 7, compared with 33.3% of patients on placebo. At 6 months, 13.3% of treated patients had died, compared with 43.3% in the placebo group. Hospital stays were also shorter. The results have not yet been peer reviewed, and Nano24 plans a larger international phase 3 trial.

Next, the FDA has granted fast track designation to Nuravax’s AV-1959R, an investigational vaccine designed to prevent Alzheimer disease. The vaccine is intended for people who have no symptoms but show biomarker evidence of amyloid buildup in the brain. In a small phase 1 study, all 12 people who received the vaccine developed antibodies against amyloid-beta. Nuravax plans to test the vaccine in a 160-person phase 2 trial that will track safety, immune response, and changes in amyloid and tau. No preventive therapy is currently approved for this population.

And Bionyra Pharma’s long-acting antibody BYN-002 has shown an extended half-life in an early-stage study. The antibody targets T-L-1-A, a protein that drives inflammation in inflammatory bowel disease. In interim phase 1 results from healthy volunteers, the antibody’s half-life reached roughly 78 to 82 days in the repeat-dosing groups, and its target remained suppressed at every dose tested. No treatment-related serious side effects were reported. Bionyra says the profile could support maintenance dosing every 3 to 6 months, which could ease the treatment burden for patients.

That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways

  • ARDS survival: Inhaled EXO-CD24 lowered mortality and kept more patients free of respiratory failure in a phase 2b trial.
  • Alzheimer prevention: AV-1959R earned FDA fast track designation ahead of a 160-person phase 2 prevention study.
  • Longer dosing intervals: BYN-002’s roughly 80-day half-life could support maintenance dosing every 3 to 6 months in IBD.

Related to this article

View more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more